NCT04866602View on ClinicalTrials.gov

Atoguanil BA Study

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 17, 2021

Primary Completion Date

March 18, 2022

Study Completion Date

March 18, 2022

Conditions
Bioavailability
Interventions
DRUG

Atoguanil

Atovaquone + Proguanil free base:125 mg: 87 mg, 4 tablets

DRUG

Malarone

Atovaquone + Proguanil HCl: 250 mg: 100 mg, 4 tablets

Trial Locations (1)

SE1 1YR

Richmond Pharmacology Limited, London

All Listed Sponsors
collaborator

Richmond Pharmacology Limited

INDUSTRY

lead

Medicines for Malaria Venture

OTHER

NCT04866602 - Atoguanil BA Study | Biotech Hunter | Biotech Hunter